Lexicon Pharmaceuticals (NASDAQ:LXRX) Coverage Initiated by Analysts at SVB Leerink

SVB Leerink assumed coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX - Free Report) in a report issued on Tuesday, Marketbeat.com reports. The firm issued an outperform rating and a $5.00 price objective on the biopharmaceutical company's stock.

LXRX has been the topic of several other research reports. StockNews.com raised Lexicon Pharmaceuticals to a sell rating in a research report on Monday, April 15th. Needham & Company LLC reissued a hold rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, April 23rd.

Lexicon Pharmaceuticals Stock Down 1.3 %

Lexicon Pharmaceuticals stock traded down $0.02 during trading on Tuesday, hitting $1.54. 3,571,358 shares of the company were exchanged, compared to its average volume of 4,304,943. The business's 50 day moving average is $2.17 and its 200 day moving average is $1.73. Lexicon Pharmaceuticals has a 52 week low of $0.92 and a 52 week high of $3.79. The company has a market capitalization of $379.21 million, a P/E ratio of -1.95 and a beta of 1.27. The company has a current ratio of 5.60, a quick ratio of 5.58 and a debt-to-equity ratio of 1.07.

Lexicon Pharmaceuticals (NASDAQ:LXRX - Get Free Report) last announced its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.03. Lexicon Pharmaceuticals had a negative return on equity of 138.54% and a negative net margin of 14,573.20%. The business had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.68 million. Analysts predict that Lexicon Pharmaceuticals will post -0.71 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in LXRX. China Universal Asset Management Co. Ltd. raised its stake in shares of Lexicon Pharmaceuticals by 65.7% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 46,930 shares of the biopharmaceutical company's stock valued at $113,000 after purchasing an additional 18,601 shares during the period. Pinnacle Associates Ltd. raised its stake in shares of Lexicon Pharmaceuticals by 1.0% during the 1st quarter. Pinnacle Associates Ltd. now owns 1,747,830 shares of the biopharmaceutical company's stock valued at $4,195,000 after purchasing an additional 17,009 shares during the period. BVF Inc. IL raised its stake in shares of Lexicon Pharmaceuticals by 22.2% during the 4th quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company's stock valued at $37,387,000 after purchasing an additional 4,440,300 shares during the period. Cantor Fitzgerald L. P. bought a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter valued at $25,000. Finally, RPO LLC bought a new stake in shares of Lexicon Pharmaceuticals during the 4th quarter valued at $49,000. Hedge funds and other institutional investors own 74.70% of the company's stock.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.